Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
enGene Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology issuer focused on non-viral genetic medicines. The company’s SEC reports cover Nasdaq-listed common shares and warrants, emerging growth company status, clinical disclosures for detalimogene voraplasmid and the LEGEND trial, and material agreements tied to financing and operating arrangements.
Recent filings include Form 8-K reports on clinical and financial updates, amendments to a loan and security agreement, an at-the-market sales agreement under a shelf registration statement, executive compensation arrangements, and the completed corporate name change from enGene Holdings Inc. Proxy materials cover annual meeting matters, audited financial statements, director elections, auditor appointment, governance proposals, and shareholder voting procedures.
enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.
Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”
enGene Holdings Inc. filed an Amendment No. 1 Schedule 13G/A reporting that Cormorant Asset Management, LP and Bihua Chen hold 0 shares of Common Stock, representing 0% of the class. The filing cites 66,989,466 shares outstanding as of March 3, 2026.
The statement clarifies the reporting persons act as investment adviser to certain funds and that the filing should not be construed as an admission of beneficial ownership under Section 13. The signature date shown is May 15, 2026.
BML Investment Partners, L.P. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 6,669,908 common shares of enGene Holdings Inc. The filing states these shares represent 9.95% of the class as of the report and lists shared voting and shared dispositive power over those shares. The filing identifies the reporting person as BML Investment Partners, L.P. (a Delaware limited partnership) and discloses that BML Capital Management, LLC and Braden M. Leonard are indirect owners/agents with signature dated 05/14/2026.
enGene Holdings Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 5,225,000 common shares, representing 7.8% of the class as shown on 05/08/2026. The filing states shared voting and dispositive power over these shares through BML Capital Management, LLC and Braden M. Leonard.
enGene Therapeutics Inc. is asking shareholders to vote at a virtual-only annual general meeting on June 9, 2026. Holders of common shares at the April 28, 2026 record date can participate online, vote, and submit questions via live audio webcast.
Shareholders will vote on electing four directors to three-year terms and on appointing KPMG as auditors, with the board recommending “FOR” on both items. Quorum requires at least two persons representing at least 33⅓% of shares entitled to vote.
enGene Therapeutics Inc. reported updated interim results from the pivotal Cohort 1 of its Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC, and amended the employment agreement of Dr. Hussein Sweiti. Among 125 patients, detalimogene achieved a 54% complete response rate at any time and 43% at six months, with a low 3.2% progression rate to muscle-invasive or more advanced disease. Treatment-related adverse events occurred in 55% of patients, were mainly Grade 1–2, and led to dose interruptions or discontinuations in 2.4% of patients each. A Kaplan-Meier estimate showed a 12‑month complete response rate of 25%, and later-enrolling patients had lower response rates than earlier subgroups, which the company is further analyzing.
enGene Therapeutics Inc. holders led by Invus-related entities and Avicenna reported beneficial ownership positions in an amended Schedule 13G/A. As of March 31, 2026, Invus Public Equities directly held 4,513,228 shares and Avicenna Life Sci Master Fund directly held 739,931 shares. The filing states percentages based on 66,989,466 Shares outstanding as of March 3, 2026, with Invus Public Equities and related reporting persons shown at 6.7% and Mr. Raymond Debbane shown at 7.8%.
The cover and Item 4 describe control relationships among Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, Avicenna GP, Ulys and Mr. Debbane; each reporting person certifies the holdings were not acquired to change control. Signatures are dated May 5, 2026.
enGene Therapeutics Inc., formerly enGene Holdings Inc., has changed its corporate name to enGene Therapeutics Inc., effective April 8, 2026. The amendment affects only the name; no other changes were made to the company’s articles. The company’s common shares and warrants will continue trading on Nasdaq under the symbols ENGN and ENGNW, respectively.
In a related press release, enGene explained that the new name reflects its transition toward potential commercialization of its lead gene therapy detalimogene voraplasmid. The company plans a Biologics License Application submission for detalimogene in the second half of 2026, targeting potential approval and a commercial organization in 2027.
enGene Holdings Inc. is offering up to $100,000,000 of common shares in an at‑the‑market (ATM) program to be sold from time to time through Leerink Partners LLC as sales agent.
The sales agent may sell shares on Nasdaq (symbol ENGN) using commercially reasonable efforts and will receive commissions of up to 3.0% of gross sales. The prospectus supplement cites a last reported sale price of $8.71 per share on March 5, 2026. The company reported 66,989,466 common shares outstanding as of March 5, 2026, and the prospectus shows a pro forma example of up to 78,470,522 shares outstanding assuming sale of 11,481,056 shares at $8.71. Proceeds, if any, will be used primarily to fund clinical development of detalimogene and for general corporate purposes.